Results of a comparative valuation of the efficiency of using the plasmid construct pBud-VEGF165-FGF2 in models of autograft of the sciatic nerve defect and tubulation with the NeuraGen® collagen tube
| Autor: | R. F Masgutov, G. A Masgutova, L. R Mukhametova, K. F Idrisova, A. F Mullakhmetova, V. Y Syromiatnikova, A. A Bogov, I. I Salafutdinov, S. S Arkhipova, R. Z Salikhov, A. A Rizvanov |
|---|---|
| Rok vydání: | 2020 |
| Předmět: | |
| Zdroj: | Genes & Cells. 15:61-65 |
| ISSN: | 2500-2562 2313-1829 |
| Popis: | Traumatic injuries of peripheral nerves lead to profound disability in patients with partial or total loss of limb function. There remains the question about the use of technologies for detecting defects of the peripheral nerve with concurrent of its regeneration. In the study it has been investigated the effect of the gene-therapeutic plasmid construct pBud-VEGF165-FGF2 with various methods of overcoming 5 mm diastasis of the sciatic nerve: nerve autograft and tubulation with the NeuraGen® tube. In the study groups, assessment of sciatic nerve regeneration was based on functional and morphometric parameters. Direct injection of plasmid pBud-VEGF165-FGF2 stimulates regeneration and restoration of motor function in both groups, but with different efficacy. Comparative analysis of nerve defect replacement in combination with direct gene therapy showed the most effective approach with autologous insertion replacement by comparison to the NeuraGen. Thus, on the basis of the obtained data, we can assert that nerve autograft of the peripheral nerve remains the "gold standard” and provides the best hope of research in combination with the use of various regeneration stimulants. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|